[{"id":"be8a2507-7795-446b-88e5-5aa233ecd75d","acronym":"KEYNOTE-F49","url":"https://clinicaltrials.gov/study/NCT05763004","created_at":"2023-03-10T15:01:24.930Z","updated_at":"2025-02-25T16:18:38.185Z","phase":"Phase 1","brief_title":"A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05763004 - KEYNOTE-F49","lead_sponsor":"ImmunOs Therapeutics AG","biomarkers":" PD-L1 • PD-1 • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IOS-1002"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-10-07"}]